Dana-Farber Cancer Institute

Boston, MA

Sorting 29 by

Accepting patients

ACCELERATE

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Post-Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
  • Natural Killer Cells
  • Chemotherapy
  • Phase 1

Accepting patients

LP-118

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
  • BCL-2 Inhibitor
  • Bcl/xL Inhibitor
  • Phase 1

Accepting patients

BXCL701

BXCL701 Phase 1 R/​R Acute Myeloid Leukemia or Myelodysplastic Syndrome
  • Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
  • Phase 1

Accepting patients

AZTOUND

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
  • DNMT1 Inhibitor
  • Phase 2/3
  • Has results

Accepting patients

Eganelisib

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  • PI3K Inhibitor
  • Randomization
  • Phase 1

Accepting patients

MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
  • Bispecific Antibody
  • Phase 1

Accepting patients

TRX-103

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
  • T Cell (Allogeneic)
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

IS-free Treg Stem Cell Transplant

A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2